Skip to main content
Figure 3 | Journal of Translational Medicine

Figure 3

From: Phase 1 studies of the safety and immunogenicity of electroporated HER2/CEA DNA vaccine followed by adenoviral boost immunization in patients with solid tumors

Figure 3

Frequencies of CEA and HER2/neu specific IFN-γ producing T cells following high-dose V930 DNA-EP vaccination. Longitudinal frequencies were determined from evaluable subjects (n=14); the threshold for CMI response was ≥35 SFC/106 PBMC and ≥3.5-fold above mock (i.e., control well levels [red line]). Differences between time points or between CEA and HER2 and mock were not significant (P>0.05 by Wilcoxon rank sum test). Arrow shows day of last V930-DNA-EP vaccination.

Back to article page